omega 3 fatty and doxorubicin-induced cardiotoxicity in children with acute lymphoblastic leukemia

Can omega 3 fatty acid reduce doxorubicin-induced cardiotoxicity in children with acute lymphoblastic leukemia

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

PACTR

Registry ID

PACTR202004884348172

Enrollment

Registered

2020-04-02

Start date

2020-02-15

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Interventions

treatment group with omega 3

none

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: children aged less than 18 years with ALL treated with doxorubicin

Exclusion criteria

Exclusion criteria: children with congenital or acquired heart disease, children with renal or hepatic disorder.

Design outcomes

Primary

Measure	Time frame
cardiac function by echocardiography	—

Secondary

Measure	Time frame
serum malondialdhyde, glutathione, superoxide dismutase and the cardiac markers troponin I and CK-MB	—

Countries

Egypt

Contacts

Public ContactAmr Zoair

Professor of pediatrics and vice dean of Faculty of medicine Tanta University Egypt

azoair@hotmail.com00201001108683

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026